Relatively-subdued COVID-19 fears
23/03/20 -"With aggravating COVID-19 fears and a material effect on the pharma supply chain – especially with respect to APIs, other than already known biosimilar risks, near-term earnings pressure is ..."
Pages
64
Language
English
Published on
23/03/20
You may also be interested by these reports :
08/04/20
When we last pushed GlaxoSmithKline’s (GSK) (Add, UK) investment story in mid-2017, the newly-appointed CEO, Emma Walmsley (consumer health veteran), ...
07/04/20
Our target price moves marginally higher due to increases in the intrinsic valuations, which factor in better than expected performance in the face ...
27/03/20
Given that >50% of Faes Farma’s sales come from Spain, a region which is adversely affected with the ongoing COVID-19 crisis, we have slashed our ...
26/03/20
Well-positioned in the plasma industry, Grifols could be a winner from the ongoing pandemic crisis — as the Spanish pharma giant has joined forces ...